公开(公告)号：US20170291921A1

公开(公告)日：2017-10-12

申请号：US15512619

申请日：2015-09-18

Applicant: NATIONAL UNIVERSITY CORPORATION, IWATE UNIVERSITY ,  OSAKA CITY UNIVERSITY ,  IWATE MEDICAL UNIVERSITY EDUCATIONAL FOUNDATION ,  LOTTE CO., LTD.

Inventor： Koichi SUZUKI ,  Shinichi ISHIGURO ,  Mayumi KARIMAZAWA ,  Makiko EBATA ,  Piyamas SILLAPAKONG ,  Takashi HIRAGA ,  Masaaki TSUSHIMA ,  Tetsuro SHINADA ,  Eiji NISHIMURA ,  Yasuo TERAYAMA ,  Hideyuki YASUDA

IPC: C07K5/12 ,  A61K36/062

CPC classification number: C07K5/126 ,  A61K36/062 ,  A61K38/00 ,  C07K5/1016

Abstract: Provided is a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity, or a salt thereof.

公开(公告)号：US20160250276A1

公开(公告)日：2016-09-01

申请号：US15074142

申请日：2016-03-18

Applicant: OSAKA CITY UNIVERSITY

Inventor： Shinji Hirotsune

IPC: A61K38/05 ,  A61K9/00

CPC classification number: A61K38/05 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/00

Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

Abstract translation: 本发明的一个目的是提供一种用于治疗失精症患者的药物和方法。 本发明提供一种包含由通式（I）表示的化合物的解散性治疗剂或预防剂：其中R 1为被低级烷氧基取代的低级烷基，被杂环基取代的低级烷基，杂环基或由 式（IIa）：其中R 4为低级烷基，R 3为低级亚烷基，m为1至6的整数; R2是任选被苯基取代的低级烷基; 且R 3为任选被卤素，低级烷氧基或苯基取代的低级烷基; 稠合多环烃; 或氢气。

公开(公告)号：US20160175280A1

公开(公告)日：2016-06-23

申请号：US14902769

申请日：2014-06-02

Applicant: PUBLIC UNIVERSITY CORPORATION OSAKA CITY UNIVERSITY ,  KIYOMOTO IRON & MACHINERY WORKS CO LTD

Inventor： Akiko KOJIMA ,  Isao YUASA ,  Kunio KIYOMOTO ,  Ayano OMURA

IPC: A61K31/36 ,  A61Q19/10 ,  A61Q1/12 ,  A61K8/49 ,  A61Q19/00

CPC classification number: A61K31/36 ,  A61K8/4973 ,  A61K36/185 ,  A61Q1/12 ,  A61Q19/00 ,  A61Q19/007 ,  A61Q19/08 ,  A61Q19/10

Abstract: The present invention relates to a composition for enhancing collagen production, for enhancing elastin production and/or for enhancing keratinocyte migration, including sesaminol as an active component. The present invention also relates to a method for enhancing collagen production, for enhancing elastin production and/or for enhancing keratinocyte migration, including administering the composition.

Abstract translation: 本发明涉及用于增强胶原蛋白产生的组合物，用于增强弹性蛋白的产生和/或促进角质形成细胞的迁移，包括芝麻素作为活性成分。 本发明还涉及一种用于增强胶原产生，用于增强弹性蛋白产生和/或增强角质形成细胞迁移的方法，包括施用该组合物。

公开(公告)号：US20150257701A1

公开(公告)日：2015-09-17

申请号：US14632906

申请日：2015-02-26

Applicant: OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION ,  PUBLIC UNIVERSITY CORPORATION OSAKA CITY UNIVERSITY ,  ADVANTEST CORPORATION

Inventor： Hiromichi HORINAKA ,  Hiroyasu MORIKAWA

IPC: A61B5/00 ,  A61B8/14 ,  A61B8/08

CPC classification number: A61B5/4872 ,  A61B8/085 ,  A61B8/0858 ,  A61B8/5207 ,  A61B8/5223 ,  A61B8/5246

Abstract: A body fat diagnostic apparatus, with which a change in the velocity of ultrasonic waves can be measured and fat can be diagnosed while suppressing the effects of a periodical change due to respiration and heartbeats of a subject, is formed of: a process unit for sequentially acquiring ultrasonic wave echo signals for a number of frames so as to form a group of B mode images; a data storage unit for storing the ultrasonic wave echo signals corresponding to the groups of B mode images; a sampling unit for sampling one frame as a standard image and another frame as a comparative image through the calculation of a cross correlation; and a velocity change analyzing unit for forming an image by calculating a change in the velocity of ultrasonic waves on the basis of the ultrasonic wave echo signals corresponding to the standard image and the comparative image.

Abstract translation: 一种身体脂肪诊断装置，通过该身体脂肪诊断装置，可以测量超声波的速度变化，并且可以在抑制由于对象的呼吸和心跳引起的周期性变化的影响的同时诊断脂肪，所述装置由以下部件构成：处理单元， 获取多个帧的超声波回波信号，以形成一组B模式图像; 数据存储单元，用于存储对应于B模式图像组的超声波回波信号; 采样单元，用于通过交叉相关的计算，将一帧作为标准图像进行采样，另一帧作为比较图像; 以及速度变化分析单元，用于通过基于与标准图像和比较图像相对应的超声波回波信号计算超声波的速度的变化来形成图像。

公开(公告)号：US20150219700A1

公开(公告)日：2015-08-06

申请号：US14400023

申请日：2013-05-09

Applicant: OSAKA CITY UNIVERSITY

Inventor： Hiroaki Tsujimoto

IPC: G01R21/00 ,  G01R21/08

CPC classification number: G01R21/006 ,  G01R21/08 ,  G01R33/0029 ,  G01R33/096

Abstract: A small-sized power factor measurement apparatus capable of measuring a power factor by one element is desired. The power factor measurement apparatus includes a pair of coupling ends (12) for coupling to a power supply in parallel with a load, two magnetic elements (21, 22) whose changes in electric resistance are different from each other due to the same external magnetic field, a pair of measurement terminals (13) for outputting a differential voltage between the two magnetic elements, a power factor sensor (10) including a pair of sensor terminals (10t) connected to the pair of coupling ends (12), a voltage detector (15) for measuring a voltage between the measurement terminals (13), a low-pass filter (16) connected to the output of the voltage detector (15), a high-pass filter (17) connected to the output of the voltage detector (15), a rectifier (18) connected to the high-pass filter (17), and a divider (19) for dividing the output of the low-pass filter (16) and the output of the rectifier (18).

Abstract translation: 期望能够通过一个元件测量功率因数的小尺寸功率因数测量装置。 功率因数测量装置包括一对用于与负载并联耦合到电源的耦合端（12），两个磁性元件（21,22）由于相同的外部磁性而彼此不同 用于输出两个磁性元件之间的差分电压的一对测量端子（13），包括连接到所述一对耦合端（12）的一对传感器端子（10t）的功率因数传感器（10），电压 检测器（15），用于测量测量端子（13）之间的电压，连接到电压检测器（15）的输出的低通滤波器（16），连接到电压检测器（15）的输出的高通滤波器 电压检测器（15），连接到高通滤波器（17）的整流器（18）和用于分压低通滤波器（16）的输出和整流器（18）的输出的分压器（19） 。

公开(公告)号：US20150183854A1

公开(公告)日：2015-07-02

申请号：US14403803

申请日：2013-05-30

Applicant: OSAKA CITY UNIVERSITY ,  TEIJIN PHARMA LIMITED

Inventor： Hiroshi Mori ,  Takami Tomiyama ,  Yoichi Matsumoto ,  Hiroshi Eguchi ,  Yuichi Kunori

IPC: C07K16/18 ,  C07K14/47

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K14/4711 ,  C07K2317/24 ,  C07K2317/565

Abstract: [SUMMARY][PURPOSE]The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders.[SOLUTION MEANS]The invention provides an antibody that participates in antigen-antibody reaction specifically with tau protein that has been phosphorylated in the vicinity of Ser413 of SEQ ID NO: 1, and a therapeutic agent or prophylactic agent for cognitive disorders comprising as an active ingredient a peptide that has been phosphorylated in the vicinity of Ser413.

Abstract translation: 发明内容本发明提供了一种用于认知障碍的新型治疗剂或预防剂。 [解决方案]本发明提供参与抗体 - 抗体反应的抗体，特异性地与在SEQ ID NO：1的Ser413附近被磷酸化的tau蛋白，以及包含作为活性的认知障碍的治疗剂或预防剂 成分在Ser413附近被磷酸化的肽。

公开(公告)号：US20150011745A1

公开(公告)日：2015-01-08

申请号：US14358509

申请日：2012-11-14

Applicant: Osaka City University

Inventor： Akira Tachibana ,  Toshizumi Tanabe

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/711 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/3231 ,  C12N2310/3519 ,  C12N2310/50 ,  C12N2310/531 ,  C12N2310/533 ,  C12N2320/30

Abstract: The purpose of the present invention is to develop and provide a nucleic acid molecule that can specifically and efficiently inhibit the activity of a target RNAi molecule and can be produced safely at a low cost. Provided is a nucleic acid molecule for inhibiting the activity of a target RNAi molecule. The nucleic acid molecule comprises a single-stranded nucleic acid moiety that contains one unmodified DNA region composed of a nucleotide sequence completely or sufficiently complementary to a nucleotide sequence of a functional strand having the activity in the target RNAi molecule and a double-stranded nucleic acid moiety to be linked to at least one of the 5′-end and the 3′-end of the single-stranded nucleic acid moiety.

Abstract translation: 本发明的目的是开发和提供能够特异性且有效地抑制靶RNAi分子的活性并可以以低成本安全地制备的核酸分子。 提供了用于抑制靶RNAi分子的活性的核酸分子。 核酸分子包含单链核酸部分，其含有由与靶RNAi分子中具有活性的功能链的核苷酸序列完全或充分互补的核苷酸序列构成的一个未修饰的DNA区域和双链核酸 部分连接到单链核酸部分的5'末端和3'末端中的至少一个。

公开(公告)号：US20140315982A1

公开(公告)日：2014-10-23

申请号：US14355711

申请日：2012-11-01

Applicant: OSAKA CITY UNIVERSITY

Inventor： Akira Tachibana ,  Toshizumi Tanabe

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/7105 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/50 ,  C12N2320/51

Abstract: Provided are an improved double-stranded nucleic acid molecule involved in gene expression control mediated by a gene silencing mechanism, a method of producing the molecule, and a pharmaceutical composition comprising the double-stranded nucleic acid molecule. The double-stranded nucleic acid molecule for gene expression control comprises an antisense strand having a length of 18 to 28 nucleotides and a sense strand including a complementary moiety composed of a sequence sufficiently complementary to the antisense strand and a protruding single-stranded 5′-end moiety having a length of 2 to 100 nucleotides. The sense strand and the antisense strand form base pairs via the complementary moiety. The method produces such a double-stranded nucleic acid molecule, and the pharmaceutical composition contains such a double-stranded nucleic acid molecule as an active ingredient.

Abstract translation: 提供涉及由基因沉默机制介导的基因表达控制的改进的双链核酸分子，产生该分子的方法和包含双链核酸分子的药物组合物。 用于基因表达控制的双链核酸分子包含长度为18至28个核苷酸的反义链和包含由与反义链足够互补的序列构成的互补部分的有义链和突出的单链5'- 末端部分具有2至100个核苷酸的长度。 有义链和反义链通过互补部分形成碱基对。 该方法产生这样的双链核酸分子，并且该药物组合物含有作为活性成分的这种双链核酸分子。

公开(公告)号：US10750988B2

公开(公告)日：2020-08-25

申请号：US16270794

申请日：2019-02-08

Applicant: OMRON HEALTHCARE Co., Ltd. ,  OSAKA CITY UNIVERSITY

Inventor： Kenji Fujii ,  Shingo Yamashita ,  Yasuyoshi Watanabe ,  Kei Mizuno

IPC: A61B5/00 ,  A61B5/16 ,  A61B5/0245 ,  A61B5/024

Abstract: A fatigue degree determination device includes a fatigue degree determination unit. A first biological heart rate is acquired while a user is awake and at rest, based on a biological heart rate measured from the user. A second biological heart rate is acquired while the user is sleeping, based on the biological heart rate measured from the user. The fatigue degree determination unit determines a fatigue degree of the user, based on information read out from a storage medium, the first biological heart rate and the second biological heart rate. The storage medium stores the information in which a degree of change of one biological heart rate relative to the other biological heart rate of a biological heart rate while a person is awake and at rest and a biological heart rate while the person is sleeping and a fatigue degree are associated with each other.

公开(公告)号：US20190193015A1

公开(公告)日：2019-06-27

申请号：US16255876

申请日：2019-01-24

Applicant: IHI Corporation ,  OSAKA CITY UNIVERSITY

Inventor： Yoshiyuki ISO ,  Ryosuke IKEDA ,  Shiko NAKAMURA ,  Kenji KATOH ,  Tatsuro WAKIMOTO

IPC: B01D47/14 ,  B01J19/32

CPC classification number: B01D47/14 ,  B01J10/00 ,  B01J19/32 ,  B01J2219/32206 ,  B01J2219/3221 ,  B01J2219/32234 ,  B01J2219/32408 ,  B01J2219/328

Abstract: The packing has one or more thin-layer packing elements that are installed upright, the packing element having a main body portion with a planar liquid film formation surface, and one or more wall portions that are provided upright relative to the liquid film formation surface along a linear direction. The side surface of each wall portion has a curved portion at the base thereof connected to the liquid film formation surface, the curved portion curbing so as to continue into the liquid film formation surface.